Carregant...
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies
BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating fa...
Guardat en:
| Publicat a: | J Immunother Cancer |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7223469/ https://ncbi.nlm.nih.gov/pubmed/32376721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000368 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|